Journal of voice : official journal of the Voice Foundation · 2025
Influence of Inhaled Corticosteroids on Voice Quality: A Systematic Review.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lechien Jérôme R
Аннотация
OBJECTIVE: To investigate the incidence of dysphonia and the related voice quality assessment impairment in patients treated with inhaled corticosteroids.
METHODS: A laryngologist and librarian conducted a PubMED, Scopus, and Cochrane Library systematic review related to the voice quality features in patients treated with inhaled corticosteroids through the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements.
RESULTS: Of the 366 identified studies, 21 publications met inclusion criteria (15 026 subjects). Dysphonia prevalence ranged from 3.0% to 34.0% according to patients and 53.3%-89.0% according to practitioners. Subjective, laryngostroboscopic, and objective voice evaluations (aerodynamic and acoustic) showed impairments influenced by IC doses, treatment duration, and particle sizes. Mean MINORS score was 5.8 ± 2.1. Substantial heterogeneity existed across studies regarding IC drugs, inclusion/exclusion criteria, and outcomes. There was no study considering a multidimensional voice quality evaluation. Most studies failed to address key confounding factors, including laryngopharyngeal reflux disease, tobacco consumption, and active allergic rhinitis.
CONCLUSION: Inhaled corticosteroids significantly impact voice quality, with substantial discrepancy between patient-reported and clinician-reported dysphonia rates. The drug features influence the occurrence of dysphonia, despite methodological limitations. Future research requires standardized multidimensional voice quality assessments and better control of confounding factors to clarify the underlying pathophysiological mechanisms.
METHODS: A laryngologist and librarian conducted a PubMED, Scopus, and Cochrane Library systematic review related to the voice quality features in patients treated with inhaled corticosteroids through the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements.
RESULTS: Of the 366 identified studies, 21 publications met inclusion criteria (15 026 subjects). Dysphonia prevalence ranged from 3.0% to 34.0% according to patients and 53.3%-89.0% according to practitioners. Subjective, laryngostroboscopic, and objective voice evaluations (aerodynamic and acoustic) showed impairments influenced by IC doses, treatment duration, and particle sizes. Mean MINORS score was 5.8 ± 2.1. Substantial heterogeneity existed across studies regarding IC drugs, inclusion/exclusion criteria, and outcomes. There was no study considering a multidimensional voice quality evaluation. Most studies failed to address key confounding factors, including laryngopharyngeal reflux disease, tobacco consumption, and active allergic rhinitis.
CONCLUSION: Inhaled corticosteroids significantly impact voice quality, with substantial discrepancy between patient-reported and clinician-reported dysphonia rates. The drug features influence the occurrence of dysphonia, despite methodological limitations. Future research requires standardized multidimensional voice quality assessments and better control of confounding factors to clarify the underlying pathophysiological mechanisms.